AMYLOIDOSIS
Clinical trials for AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy aims to halt rare, devastating nerve disease
Disease control OngoingThis Phase 3 trial is testing whether a single dose of an experimental gene therapy called NTLA-2001 can safely slow or stop the progression of hereditary amyloidosis with polyneuropathy (ATTRv-PN), a rare genetic disease that damages nerves. About 50 participants worldwide will …
Matched conditions: AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New chemo formula aims for fewer side effects in cancer fight
Disease control OngoingThis study is testing a new, more stable version of a standard chemotherapy drug called melphalan. The goal is to see if this new formulation can be dosed more precisely and might cause fewer side effects like kidney or heart damage. It is for adults with multiple myeloma or AL a…
Matched conditions: AMYLOIDOSIS
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug combo tested for rare, Heart-Damaging protein disease
Disease control OngoingThis study is testing a treatment called D-VCd (daratumumab plus other drugs) for people newly diagnosed with AL amyloidosis, a rare disease where abnormal proteins build up and damage organs, especially the heart. The main goals are to check the treatment's safety for the heart …
Matched conditions: AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Mar 02, 2026 15:27 UTC